source
- STAT+: Why big digital health players are missing from Medicare’s chronic care experimentIn this edition of STAT Health Tech: Why big digital health players skipped Medicare's ACCESS pilot, Isomorphic's big raise, and more.STAT · 2mo ago↗ source
- STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much moreBiogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tauSTAT · 2mo ago↗ source
- With new data, Regenxbio to seek FDA approval of Duchenne gene therapyThough two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”